GIPR Function in the Central Nervous System: Implications and Novel Perspectives for GIP-Based Therapies in Treating Metabolic Disorders.

Abstract

During the past decade, pharmaceutical engineering of unimolecular agents has revealed the therapeutic potential of glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism. From this work, one of the most intriguing findings is that engagement of GIPR enhances the weight loss profile of glucagon-like peptide 1 (GLP-1)-based therapeutics. Consequently, this pharmacological approach, in combination with novel Gipr mouse models, has provided evidence indicating that activation of GIPR in certain areas of the brain that regulate energy balance is required for the synergistic weight loss of dual GIPR and GLP-1 receptor (GLP-1R) agonism. This has led to significant interest in understanding how GIPR activity in the brain functions to reduce caloric intake, induce negative energy balance, and drive weight loss. Herein, we review key findings in this field and provide a novel perspective explaining how GIP may act in the brain to affect energy balance both alone and in concert with GLP-1R agonism.

• Authors: Ricardo J Samms, Kyle W Sloop, Fiona M Gribble, Frank Reimann, Alice E Adriaenssens
• Journal: Diabetes (Diabetes) Vol. 70 Issue 9 Pg. 1938-1944 (09 2021) ISSN: 1939-327X [Electronic] United States
• PMID: 34176786 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
• Copyright: © 2021 by the American Diabetes Association.

Chemical References

• Glucagon-Like Peptide-1 Receptor
• Receptors, Gastrointestinal Hormone
• Gastric Inhibitory Polypeptide
• Glucagon-Like Peptide 1
• gastric inhibitory polypeptide receptor

Topics

• Animals
• Brain (metabolism)
• Gastric Inhibitory Polypeptide (metabolism)
• Glucagon-Like Peptide 1 (metabolism)
• Glucagon-Like Peptide-1 Receptor (metabolism)
• Humans
• Metabolic Diseases (drug therapy, metabolism)
• Receptors, Gastrointestinal Hormone (metabolism)